Data from Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer

Abstract

<div>Abstract<p>Microscaled proteogenomics was deployed to probe the molecular basis for differential response to neoadjuvant carboplatin and docetaxel combination chemotherapy for triple-negative breast cancer (TNBC). Proteomic analyses of pretreatment patient biopsies uniquely revealed metabolic pathways, including oxidative phosphorylation, adipogenesis, and fatty acid metabolism, that were associated with resistance. Both proteomics and transcriptomics revealed that sensitivity was marked by elevation of DNA repair, E2F targets, G<sub>2</sub>–M checkpoint, interferon-gamma signaling, and immune-checkpoint components. Proteogenomic analyses of somatic copy-number aberrations identified a resistance-associated <i>19q13.31–33</i> deletion where <i>LIG1</i>, <i>POLD1</i>, and <i>XRCC1</i> are located. In orthogonal datasets, <i>LIG1</i> (DNA ligase I) gene deletion and/or low mRNA expression levels were associated with lack of pathologic complete response, higher chromosomal instability index (CIN), and poor prognosis in TNBC, as well as carboplatin-selective resistance in TNBC preclinical models. Hemizygous loss of <i>LIG1</i> was also associated with higher CIN and poor prognosis in other cancer types, demonstrating broader clinical implications.</p>Significance:<p>Proteogenomic analysis of triple-negative breast tumors revealed a complex landscape of chemotherapy response associations, including a <i>19q13.31–33</i> somatic deletion encoding genes serving lagging-strand DNA synthesis (<i>LIG1</i>, <i>POLD1</i>, and <i>XRCC1</i>), that correlate with lack of pathologic response, carboplatin-selective resistance, and, in pan-cancer studies, poor prognosis and CIN.</p><p><i><a href="https://aacrjournals.org/cancerdiscovery/article/doi/10.1158/2159-8290.CD-12-11-ITI" target="_blank">This article is highlighted in the In This Issue feature, p. 2483</a></i></p></div>